more

Summit Therapeutics (SMMT)

(Delayed Data from NSDQ)

$21.10 USD

+0.21 (1.01%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $21.10 0.00 (0.00%) 6:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

Top 32% (81 out of 251)

Industry: Medical - Drugs

View All Zacks #1 Ranked Stocks

Zacks News

Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales

by Zacks Equity Research Published on October 31,2024

SMMT's third-quarter earnings miss estimates. Management also provides updates on the company's pipeline.

Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?

by Zacks Equity Research Published on October 24,2024

Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.

Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold?

by Zacks Equity Research Published on October 23,2024

The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the next standard of care in the NSCLC space.

Instil Bio Stock Skyrockets 641% in One Week: Here's Why

by Zacks Equity Research Published on September 16,2024

A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.

Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More

by Zacks Equity Research Published on September 12,2024

Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.

Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda

by Zacks Equity Research Published on September 10,2024

Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.

MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study

by Zacks Equity Research Published on September 10,2024

Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.

pharmaceuticals

Company News for Sep 10, 2024

by Zacks Equity Research Published on September 10,2024

Companies in The News Are: BA,SMMT,CRM,META

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

by Zacks Equity Research Published on July 18,2024

Smart Beta ETF report for FYC

Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

by Zacks Equity Research Published on July 12,2024

Style Box ETF report for FYC

Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why

by Zacks Equity Research Published on June 12,2024

Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.

medical

Summit Therapeutics PLC (SMMT) Moves 17.4% Higher: Will This Strength Last?

by Zacks Equity Research Published on May 19,2021

Summit Therapeutics PLC (SMMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

SMMTPositive Net Change

Summit Therapeutics (SMMT) Surges: Stock Moves 7.2% Higher

by Zacks Equity Research Published on December 16,2020

Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

SMMTPositive Net Change

medical

New Strong Sell Stocks for October 30th

by Zacks Equity Research Published on October 30,2020

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research Published on June 02,2020

In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.75, marking a +1.08% move from the previous day.

SMMTPositive Net Change

Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on June 01,2020

Is (SMMT) Outperforming Other Medical Stocks This Year?

SMMTPositive Net Change

Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research Published on May 27,2020

Summit Therapeutics PLC (SMMT) closed at $4.20 in the latest trading session, marking a +1.94% move from the prior day.

SMMTPositive Net Change

Summit Therapeutics PLC (SMMT) Stock Moves -0.43%: What You Should Know

by Zacks Equity Research Published on May 19,2020

In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.48, marking a -0.43% move from the previous day.

SMMTPositive Net Change

Will Ventilator Sales Drive Medtronic's (MDT) Q4 Earnings?

by Zacks Equity Research Published on May 18,2020

Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.

CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on May 13,2020

On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.